Seeking an optimal renal replacement therapy for the chronic kidney disease epidemic: the case for on-line hemodiafiltration.

The prevalence of chronic kidney disease (CKD) can be expected to increase dramatically in the foreseeable future, with suggestions that it has already reached epidemic proportions. The inadequate supply of donor organs, aggravated by an aging patient population, necessitates provision of sustainable dialysis treatment modalities. These treatment modalities must not only be of established clinical efficacy and effectiveness, but must simultaneously circumvent any potential treatment disparities due to geographical, social or other concurring factors. Home therapies might represent a partial solution to the complex issue of seeking optimal strategies to cope with the CKD epidemic. However, self-care renal replacement therapy (RRT), such as peritoneal dialysis (PD) and home therapies, can only be applied to a limited portion of the CKD population. Consequently, in preparation for coping with this CKD epidemic, specific large-scale plans need to be made that involve optimization of treatments already in use for the majority of the population requiring RRT, e.g. hemodialysis (HD). Extracorporeal chronic HD relies heavily on technology for its clinical success. Like the choice of the treatment modality and the complete medical approach to CKD patient care, the particular selection of the various components of the extracorporeal circuit has a significant impact on the well-being and survival of the patients. We present a medical-technological assessment of how best to treat vast numbers of dialysis patients under the financial restraints that are predicted to become even more severe as CKD entrenches itself as a more 'permanent epidemic'. A treatment modality is proposed that optimally addresses--and resolves--the debilitating effects of uremia, as well as of key clinical conditions closely linked to it. This treatment modality successfully tackles the issues of patient well-being, efficacy, effectiveness, safety and patient-nursing staff convenience--all in relation to the overall costs incurred by payers of renal care. In short, optimal care needs to be provided with shrinking resources and without compromising the medical appropriateness of the therapy. Additionally, we believe ensuring improved quality of life is just as important as prolonging patient survival. Therefore, a balanced compromise between optimal and affordable technology is required in order to reach the targets of achieving good medical care and meeting the expectations of patients, their families, healthcare providers, and society as a whole. Under these premises, and focusing on the aforementioned targets, we believe that on-line hemodiafiltration (HDF) represents the most advanced and clinically appropriate RRT modality available to best cope with the CKD epidemic. Together with the guidance and recommendations of those taking care of CKD patients on dialysis therapy, the contribution of industry is indispensable for the availability of highly reliable and affordable solutions to the impending dilemma. As representatives of the academic-medical community and of industry, we present a joint case for the application of on-line HDF towards meeting the challenge of large-scale provision of dialysis under an increasingly restrictive financial climate.